文献速递皮肤肿瘤

既往放疗可提高西米普利单抗治疗局部晚期及转移性皮肤鳞状细胞癌的疗效:一项回顾性分析

Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis.
PubMed 文献 · J Am Acad Dermatol · 2024-06-15

BACKGROUND: Cemiplimab, a programmed cell death-1 inhibitor approved in 2018 for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) who are ineligible for curative therapies, lacks clarity regarding the optimal patient selection despite its know…

要点

  • 既往放疗与西米普利单抗治疗cSCC的PFS改善显著相关。
  • 中位随访18个月时中位PFS和OS未达到。
  • 提示放疗联合西米普利单抗的潜在价值。

核心结论

  • 既往放疗与西米普利单抗治疗的皮肤鳞状细胞癌患者无进展生存期改善显著相关。

主要发现

  • 中位随访18个月时,中位无进展生存期和总生存期均未达到,均值分别为21.3±2.2个月和25.3±2.1个月。

临床怎么用

  • 对于接受西米普利单抗治疗的局部晚期或转移性皮肤鳞状细胞癌患者,既往放疗史可能提示更好的无进展生存获益。
  • 可考虑进一步探索放疗与西米普利单抗联合的治疗策略。

局限性

  • 研究为回顾性性质。
  • 分析的患者数量较少。
  • 存在固有偏倚的潜在可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cemiplimab, a programmed cell death-1 inhibitor approved in 2018 for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) who are ineligible for curative therapies, lacks clarity regarding the optimal patient selection despite its known efficacy. OBJECTIVE: This retrospective study aims to assess the real-world treatment patterns and outcomes in patients with cSCC at our institution. METHODS: A retrospective analysis of consecutively treated patients with cemiplimab for cSCC was conducted. Progression-free survival (PFS) and overall survival were evaluated alongside clinical-pathologic characteristics. RESULTS: Forty-five patients were included, of which 73.3% were male with a median age of 77 years. After 18 months of median follow-up median PFS and overall survival were not reached with a mean of 21.3 months ± 2.2 months and 25.3 ± 2.1 months, respectively. Univariate and multivariate analyses revealed significant correlations only between PFS and previous radiotherapy (P values: .043 and .046, respectively). LIMITATIONS: Limitations include its retrospective nature, the low number of patients analyzed, and the potential for inherent biases. CONCLUSIONS: The study reveals a significant association between prior radiotherapy and improved PFS in cemiplimab-treated cSCC, suggesting the potential for combining radiotherapy with cemiplimab. Further exploration of this combined approach is warranted.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Nardone V, Napolitano S, Gagliardi F, et al. Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis. J Am Acad Dermatol. 2024. PMID: 38885840. doi:10.1016/j.jaad.2024.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。